Drugs /

aip-303

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for aip-303

Aip-303 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating aip-303, 1 is phase 1/phase 2 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for aip-303 clinical trials.

Breast carcinoma is the most common disease being investigated in aip-303 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Aip-303
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating aip-303 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.